Betamethasone dipropionate was patented by Merck in 1987 as an augmented cream/lotion, Diprolene in the ., and Disprosone in Europe.  These patents expired in 2003 and 2007 respectively leading to generic production of betamethasone dipropionate. During this time other topical corticosteroids such as triamcinolone acetonide and clobetasol propionate also became available as generic creams. Merck filed for "pediatric exclusivity" in 2001 launching a clinical trial to prove betamethasone dipropionate's safety and efficacy for use in pediatrics. 
Important Safety Information for Clobex ® (clobetasol propionate) Lotion, %
Clobex ® (clobetasol propionate) Lotion, %, is not recommended for anyone younger than 18 years of age.
Clobex ® Lotion is indicated to treat steroid-responsive dermatoses. Treatment of steroid responsive dermatoses (eczema, dermatitis) should be limited to 2 weeks. Use only as directed by your physician, and do not apply to your face, underarms, or groin and avoid contact with your eyes and lips.
The total dosage should not exceed 50 g (50 mL or fl oz) per week. You should use Clobex ® Lotion only for the minimum period necessary to achieve desired results. In clinical trials, patients reported burning/stinging, skin dryness, irritation, redness, itching, skin thinning and widening of blood vessels. Because too much Lotion passing through your skin may affect your adrenal glands, do not use more than prescribed and stop using the product if you experience nausea, vomiting, fever or low blood pressure, and call you doctor. If you are pregnant, trying to get pregnant or nursing, speak to your doctor before using Clobex ® Lotion.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit /medwatch , or call 1-800-FDA-1088 (1-800-332-1088).
"Studies in the rat following oral administration at dosage levels up to 50 mcg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Pregnancy: Teratogenic Effects (., possibility of causing abnormalities in fetuses): Pregnancy Category C: Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less are no adequate and well-controlled studies of the teratogenic effects of clobetasol propionate in pregnant women. Temovate Cream and Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."